Cloning and Mutagenesis Global Market Report 2024

The cloning and mutagenesis market has grown exponentially in recent years. It will grow from $2.53 billion in 2023 to $3.05 billion in 2024 at a compound annual growth rate (CAGR) of 20.6%. The expansion observed in the historical period can be ascribed to progress in genetic research, heightened demand for pharmaceutical research, the surge of genetic engineering in agriculture, applications in biomedical research, and pioneering applications in molecular biology.

The cloning and mutagenesis market is expected to see rapid growth in the next few years. It will grow to $6.07 billion in 2028 at a compound annual growth rate (CAGR) of 18.8%. The anticipated growth in the forecast period can be linked to the widening applications in gene therapy, increasing demand for personalized medicine, advancements in functional genomics, innovations in synthetic biology, and applications in agricultural biotechnology. Major trends expected in the forecast period include targeted gene editing in therapeutics, improved precision and specificity, customizable molecular tools, expanded applications in agriculture, and considerations related to ethics and regulations.

The cloning and mutagenesis market is expected to experience growth driven by the rising demand for genetically modified products. Genetically modified products involve organisms, materials, or substances that undergo deliberate genetic engineering to introduce new traits or characteristics. Cloning, a scientific process for producing exact genetic copies, is utilized in various applications, including creating insect and plant-resistant species and facilitating gene therapy in medical sciences. An annual report from Bayar AG, a Germany-based biotechnology and pharmaceutical company, revealed significant growth in the sales of genetically modified products, with the crop sciences segment reaching $27,794.38 million in 2022, up from $22,314.79 million in 2021. This increased demand for genetically modified products is a key driver of the cloning and mutagenesis market. The data is based on information provided in the annual report published by Bayar AG in February 2023.

The cloning and mutagenesis market is anticipated to grow due to the increasing demand for personalized medicine. Personalized medicine is an innovative healthcare approach that tailors medical treatment and interventions to the unique characteristics of each patient. Cloning and mutagenesis play crucial roles in various aspects of personalized medicine, such as disease modeling, drug development, target identification, gene therapy, biomarker discovery, patient-specific cell therapies, pharmacogenomics, and genome editing for personalized therapies. In April 2022, the Personalized Medicine Coalition reported that the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022. Among the therapeutic NMEs, approximately 34% (12 of them) were classified as personalized medicines by the Personalized Medicine Coalition (PMC). This increasing demand for personalized medicine is a significant driver of the growth in the cloning and mutagenesis market.

Major players in the cloning and mutagenesis market are leveraging advanced technologies, such as bacteriophage genome modifying technologies, to enhance their competitive position. Bacteriophage genome modifying technologies involve intentional alterations to the genetic material of bacteriophages, viruses that infect bacteria, for applications in research, therapy, or industry. An example is iNtRON Biotechnology, a South Korea-based biotech company, which introduced its 2nd generation Robot Bacteriophage technology in October 2022. This technology utilizes random transposon mutagenesis to modify the bacteriophage genome, enabling the identification and removal of non-essential genes. iNtRON aims to design and produce bacteriophages with specific characteristics, facilitating the development of immunotherapeutic agents and antiviral solutions.

Leading companies in the cloning and mutagenesis markets are also actively exploring innovative techniques such as Polymerase Chain Reaction (PCR) to maintain a competitive edge. PCR is a molecular biology laboratory technique that amplifies specific DNA segments. Bio-Rad Laboratories, Inc., a US-based biotech company, launched the ID-Check Speciation Solution in April 2023. This real-time PCR method aids in meat speciation, allowing the identification of animal species in food, feed, and environmental samples. It provides a reliable and rapid means to verify raw material origins, enhancing production line cleaning processes. The solution targets mitochondrial DNA from various meat species with exceptional sensitivity, detecting DNA concentrations as low as 0.001%. It features a duplex detection system for accuracy and user convenience.

In April 2021, Charles River Laboratories International Inc., a US-based pharmaceutical company specializing in preclinical and clinical services, completed the acquisition of Cognate BioServices for $875 million. This strategic move is designed to position Charles River as a comprehensive solution provider, covering both fundamental research and Current Good Manufacturing Practice (CGMP) production. Cognate BioServices, the acquired entity, is a US-based biotechnology company with a focus on the development of cell and cell-mediated gene therapies. This acquisition reflects Charles River's commitment to expanding its capabilities in the field of biotechnology and reinforcing its position in the preclinical and clinical services market.

Major companies operating in the cloning and mutagenesis market report are Thermo Fisher Scientific, Takara Bio Inc., Agilent Technologies Inc., Jena Bioscience GmbH, Transgen Biotech Co, New England Biolabs, Merck KGaA, Promega Corporation, Bio-Rad Laboratories Inc., Danaher, Genomax Technologies Pte Ltd., GENEWIZ Inc., abm Inc., GenScript, EZBioscience, Codex DNA Inc., Aragen Life Sciences, Bio-Techne, Charles River Laboratories, Integrated DNA Technologies, MedGenome, Sino Biological Inc., BioChain Institute Inc., OriGene Technologies Inc., Creative Biogene, Bioneer Corporation, Synbio Technologies LLC, Lucigen Corporation, Biomatik Corporation, Quanta BioDesign Ltd., Inscripta Inc.

North America was the largest region in the cloning and mutagenesis market in 2023. Asia-pacific is expected to be the fastest-growing region in the global cloning and mutagenesis market report during the forecast period. The regions covered in the cloning and mutagenesis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cloning and mutagenesis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary products associated with cloning and mutagenesis include cloning kits, mutagenesis kits, and other related tools. Cloning kits are specialized laboratory instruments designed to streamline the process of cloning specific DNA fragments or genes into a cloning vector. These kits are essential for various cloning experiments, including gene cloning, subcloning, site-directed mutagenesis, and library construction. Techniques such as blunt end cloning, topo PCR cloning, seamless cloning, site-directed mutagenesis, among others, are employed by academic and research institutions, biotechnology companies, and other entities engaged in molecular biology research.

The cloning and mutagenesis software market research report provides cloning and mutagenesis software market statistics, including cloning and mutagenesis software industry global market size, regional shares, competitors with a cloning and mutagenesis software market share, detailed cloning and mutagenesis software market segments, market trends and opportunities, and any further data you may need to thrive in the cloning and mutagenesis software industry. This cloning and mutagenesis software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cloning and mutagenesis market includes revenues earned by entities by assay kits, biotin-peg linkers, Bira proteins, and cells. The market value includes the value of related goods sold by the service provider or included within the service offering. The cloning and mutagenesis market also includes of sales of techniques such as the isolation of DNA, cloning vectors, and DNA ligase. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.